SV Health Investors

Trial to evaluate weight loss efficacy of azelaprag, an oral small molecule apelin receptor agonist that mimics key biological effects of exercise

Montara Therapeutics closed an oversubscribed $8 million seed financing led by SV Health Investors’ Dementia Discovery Fund and co-led by Two Bear Capital, with Dolby Family Ventures and KdT Ventures participating.

The latest SV company and portfolio news

Pulse Biosciences appointed Paul A. LaViolette to its board as an independent director and co-chairman, alongside co-chairman Robert W. Duggan.

Alex joined SV in 2020 and is a Vice President in the biotech team. He helps form and fund companies developing transformational new medicines. Alex serves as a board observer at Alchemab, Dualitas, EyeBio and Therini, four SV created companies.

Dan joined SV as a Venture Partner in 2014 and is Executive Chairman or Director of a number of SV and DDF portfolio companies. Currently, he is Chair and Chief Executive Officer Pulmocide.

Jamil joined SV in 2024 as a Partner on the Biotech team

Kate co-leads SV’s biotech franchise which has a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market.

28 State Street Financial District Downtown Boston Boston Suffolk County Massachusetts 02109 United States

SV Health Investors is a specialist healthcare fund manager that invests across multiple stages and sectors.

The SV privacy policy describes the use and disclosure of personal data collected through its website and other means, including data about contacts, vendors, and prospective investors and employees.